New antibody cocktail might fight all corona variants
A nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1281 entries already.
Entries by Thomas Gabrielczyk
Ring exchange at Roche’s top executive level
/in News/by Thomas GabrielczykSchwan follows Franz, Schinecker follows Schwan.
French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site
/in News/by Thomas GabrielczykThis new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used […]
Oxford Science Enterprises raised a further £250 million ($300 million) in funding
/in News/by Thomas GabrielczykOxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a […]
Swedish Bioinvent issues shares worth SEK299m (USD28m)
/in News/by Thomas GabrielczykBioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such […]
Immunocore has a sip with USD140m private placement
/in News/by Thomas GabrielczykImmunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
Worldview national ranking of health biotech sectors
/in News/by Thomas GabrielczykA current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
GSK splits off consumer health as Haleon – first stock listing today
/in News/by Thomas GabrielczykGlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK to demerge on […]
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
/in News/by Thomas GabrielczykEuropean Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Agomab extenses Series B with USD40m Bringing Total Amount to USD114m
/in News/by Thomas GabrielczykAgomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (38.4 million), bringing the total Series B […]